6th DDR Inhibitors Summit

DNA damage response inhibition has amassed a lot of interest over the last decade as it exposes a massive vulnerability in cancer cells. This has a huge potential to treat many types of tumors such as breast and colorectal cancers, and even notoriously difficult-to-treat CNS tumors.

The 6th Annual DDR Inhibitors Summit will cover both the preclinical and clinical DDR inhibitor landscape and establish how the field is addressing the biggest hurdle to drug development – toxicity. From reviewing progress with both novel and established targets to utilizing inhibitors in combination studies and improving patient selection with improved biomarkers; this meeting will give a comprehensive and up-to-date overview of the field.

As we look to 2023 and what it has in store, this highly anticipated summit is back in person, bigger and better than ever before. As the industry-leading conference, join forward-thinking researchers from the pharmaceutical, biotech and academic community as they unite to share ideas on progress, challenges and novel solutions in the current DDRi climate.

Prices:
FULL PACKAGE: Conference + Pre-Conference Day - Drug Developer USD 4946.00
Conference Only - Drug Developer USD 2999.00
FULL PACKAGE: Conference + Pre-Conference Day - Academic USD 4246.00
Conference Only - Academic USD 2599.00
FULL PACKAGE: Conference + Pre-Conference Day - Solution Provider USD 5846.00
Conference Only - Solution Provider USD 3599.00

Speakers: Anang Shelat, Professor & Director - Compound Management & Discovery Informatics Lead, St. Jude Children’s Research Hospital, Arne Nedergaard, Koshoult Postdoc, The Netherlands Cancer Institute, Asli Muffavak, Associate Director - Scientific, Oncology, Synthetic & Lethality, GlaxoSmithKline, Charles Sinclair, Head of Translational Sciences, Pioneering Medicines, Flagship Pioneering, Chun-Pyn, Shen Vice President & Head of Regulatory Affairs, IMPACT Therapeutics, David Mankoff, Co-founder, Perelman School of Medicine at the University of Pennsylvania, Eric Brown, Co-Founder, Aprea Therapeutics, Erik Sulman, Co-Director, Brain Tumor Center, NYU Langone, Frank Zenke, Global Head DNA Damage Response Research, Translational Innovation Platform Oncology and Immuno- Oncology, EMD Serano Inc., Geoffrey Shapiro, Director, Early Drug Development Center, Dana-Farber Cancer Institute, Greg Korbel, Chief Operating Officer, Aprea Therapeutics, Ioannis Gounaris, Head of Clinical Development DDR, Merck KGaA, Jann Sarkaria, Professor - Radiation Oncology, Mayo Clinic, Jennifer Castro, Principal Scientist, Accent Therapeutics, Jing Li, Professor of Oncology & Director of Pharmacology & Metabolomics Core Wayne State, University School of Medicine, Jon Hollick, Managing Director & Head of Research, Breakpoint Therapeutics, Kara Machleidt, Global Commercialization Marketing Manager, Promega, Kieran Pinto, DDR Analyst, Beacon Intelligence, Kirk Tanner, Chief Scientific Officer, National Brain Tumor Society, Mads Daugaard, President & Chief Scientific Officer, Rakovina Therapeutics, Mark O’Connor, Chief Scientist, Early Oncology Discovery, AstraZeneca, Nader Sanai, Chief Scientific Officer & Director, Ivy Brain Tumor Centre, Nimrat Chatterjee, Assistant Professor, University of Vermont, Cancer Center, Oren Gilad, Chief Executive Officer, Aprea Therapeutics, Paul Bartell, Senior Vice-President, Companian Diagnostics, Myriad Genetics, Ranjit Bindra, Co-Founder, Modifi Bio, Sotirios Sortirou, Head of Biology & Co- Founder, FoRx Therapeutics, Steve Warner, Senior Vice President & Head of US Research, Sumitomo Pharma Oncology, Sui Xiong Cai, Senior Vice President & Chief Technology Officer Oncology, IMPACT Therapeutics, Timothy Yap, Medical Director, MD Anderson Cancer Centre, Wael Jdey, Head of In Vitro Oncology Research & Innovation Group, Onxeo

Others Details

Brochure https://go.evvnt.com/1329892-3?pid=6581